We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

SARS-CoV-2 Blocks Innate Immune Activation to Cause COVID-19 Infection, Study Suggests

By HospiMedica International staff writers
Posted on 26 Jan 2021
A new study has revealed that the SARS-CoV-2 virus replicates and spreads in the body unchecked by suppressing innate immunity, leading to the disease known as COVID-19.

A recent review article in Journal of Interferon & Cytokine Research (JICR) by researchers at the University of Texas Medical Branch at Galveston (Galveston, TX, USA) has summarized that SARS-CoV-2 blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues. IFN-I is a key component of host innate immunity that is responsible for eliminating the virus at the early stage of infection. By suppressing innate immunity, the virus replicates and spreads in the body unchecked, leading to COVID-19.

Illustration
Illustration

"SARS-CoV-2 utilizes various approaches to evade host IFN-I response, including suppression of IFN-I production and IFN-I signaling," said Hongjie Xia and Pei-Yong Shi, University of Texas Medical Branch at Galveston. "Viruses defective in antagonizing IFN-I response, in combination with replication-defective mutations, could potentially be developed as live attenuated vaccine candidates."

"Targeting innate immunity is highly attractive for therapeutic and vaccine strategies aimed at controlling SARS-CoV-2 infection and protecting against COVID-19. By revealing how the virus blocks innate immune programs we can then build approaches to restore these processes and enhance antiviral immunity," added Journal of Interferon & Cytokine Research Editor-in-Chief Michael Gale Jr., Department of Immunology and Center for Innate Immunity and Immune Disease, University of Washington.

Related Links:
University of Texas Medical Branch at Galveston


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Phototherapy Eye Protector
EyeMax2
New
Transducer Covers
Surgi Intraoperative Covers

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles